Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

Patent ExpiryNamodenosonPositive

AI Analysis

Summary

Can-Fite announced it secured an Australian patent allowance for Namodenoson, supporting development and marketing of the drug for liver and pancreatic cancer indications.

Outcome Details

Australian patent allowance secured

Importance:3/10

Sentiment:

0.60

patentAustralialiver cancerpancreatic cancerintellectual property

Related Companies

$CANF

Read the original article

Published by yahoo_finance on July 14, 2026 11:00 AM

Read Original